Related Experiment Video
Updated: Jul 12, 2026
05:16
Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
Published on: February 19, 2022
[Gastrointestinal stromal tumors (GIST)]
Przemysław J Galbfach1, Ewa B Langner, Tomasz Czapiński-Tuzikiewicz
1Kliniki Chirurgii Ogólnej i Kolorektalnej, Uniwersytetu Medycznego w Lodzi. pgalbfach@wp.pl
Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|August 31, 2007
Summary
Gastrointestinal stromal tumors (GIST) are rare. Early diagnosis via CD117 staining is crucial, as imatinib shows effectiveness even in advanced stages, though surgery remains the primary treatment.
Area of Science:
- Gastroenterology
- Oncology
- Surgical Pathology
Background:
- Gastrointestinal stromal tumors (GIST) are rare mesenchymal neoplasms of the alimentary tract.
- Diagnosis and treatment of GIST present unique challenges due to their rarity and varied presentations.
Observation:
- This study reviewed 5 GIST cases: stomach (1), rectum (2), jejunum (1), and unknown primary (1).
- Immunohistochemical staining for CD117 (c-KIT) confirmed all diagnoses.
- Surgical resection was attempted in 4 cases, but radical resection was only achieved in one due to metastases or tumor size.
Findings:
- Advanced stage disease at presentation was common.
- Four patients received imatinib chemotherapy, with satisfactory early response observed.
- Radical surgery is the preferred initial treatment, but imatinib is effective in advanced GIST.
Implications:
- Broadening histopathological examination with CD117 staining is vital for accurate GIST diagnosis.
- Timely and accurate diagnosis is critical for effective treatment, including imatinib therapy in advanced cases.
- While surgery is primary, imatinib offers a valuable therapeutic option for advanced GIST, improving patient outcomes.
